

# Laura C Coates Mb Chb

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4672778/publications.pdf>

Version: 2024-02-01

233  
papers

8,791  
citations

71004

43  
h-index

60403

85  
g-index

242  
all docs

242  
docs citations

242  
times ranked

4928  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. <i>Rheumatology</i> , 2023, 62, 606-616.	0.9	6
2	How Should We Measure Peripheral Spondyloarthritis?. <i>Journal of Rheumatology</i> , 2022, 49, 239-241.	1.0	6
3	Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS). <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 359-369.	0.5	47
4	Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feasibility study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2110576.	1.2	0
5	The state of the artâ€”psoriatic arthritis outcome assessment in clinical trials and daily practice. <i>Lancet Rheumatology</i> , The, 2022, 4, e220-e228.	2.2	3
6	Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. <i>Arthritis Research and Therapy</i> , 2022, 24, 40.	1.6	4
7	Psoriatic arthritis: prospects for the future. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210867.	1.2	4
8	Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2022, , jrheum.211322.	1.0	1
9	GRAPPA Treatment Recommendations: 2021 Update. <i>Journal of Rheumatology</i> , 2022, , jrheum.211331.	1.0	12
10	Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analysis from phase 3 trials in patients with psoriatic arthritis. <i>British Journal of Dermatology</i> , 2022, , .	1.4	1
11	Gender equity in academic rheumatology: is there a gender gap at European rheumatology conferences?. <i>RMD Open</i> , 2022, 8, e002131.	1.8	16
12	Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: a cross-sectional analysis. <i>Joint Bone Spine</i> , 2022, , 105372.	0.8	3
13	Young-GRAPPA at the Annual GRAPPA Meeting: Presentation of a New Group Within GRAPPA and Its Vision. <i>Journal of Rheumatology</i> , 2022, , jrheum.211327.	1.0	0
14	Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey. <i>Rheumatology and Therapy</i> , 2022, 9, 823-838.	1.1	1
15	Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study. <i>Lancet Rheumatology</i> , The, 2022, 4, e262-e273.	2.2	8
16	Residual Disease Associated with Suboptimal Treatment Response in Patients with Psoriatic Arthritis: A Systematic Review of Real-World Evidence. <i>Rheumatology and Therapy</i> , 2022, 9, 803-821.	1.1	11
17	Treat-to-target in psoriatic arthritisâ€”cost-effective in the biosimilar era. <i>Lancet Rheumatology</i> , The, 2022, 4, e390-e391.	2.2	4
18	P257â€”Are there regional variations in access to biological disease modifying anti-rheumatic drugs for the treatment of psoriatic arthritis in England?. <i>Rheumatology</i> , 2022, 61, .	0.9	0

#	ARTICLE	IF	CITATIONS
19	P258â€fSecukinumab Improves Physical Function and Inhibits Structural Damage in Psoriatic Arthritis PsA Patients With Sustained Remission or Low Disease Activity: Results From a Phase 3 Study. <i>Rheumatology</i> , 2022, 61, .	0.9	0
20	P260â€fSecukinumab in Patients With Psoriatic Arthritis and Axial Manifestations: Predictors of Response From the Double-blind, Randomised, Phase 3b MAXIMISE Trial. <i>Rheumatology</i> , 2022, 61, .	0.9	0
21	P273â€fFactors related to insomnia in patients with psoriatic arthritis: a cross-sectional study. <i>Rheumatology</i> , 2022, 61, .	0.9	0
22	OA33â€fThe top 10 research priorities in psoriatic arthritis: a James Lind Alliance Priority Setting Partnership. <i>Rheumatology</i> , 2022, 61, .	0.9	1
23	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031.	1.8	4
24	OA36â€fBimekizumab in patients with psoriatic arthritis: achievement and maintenance of Psoriatic Arthritis Response Criteria responses through 3 years in a phase 2b open-label extension study. <i>Rheumatology</i> , 2022, 61, .	0.9	0
25	P266â€fSecukinumab provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of five phase 3 studies. <i>Rheumatology</i> , 2022, 61, .	0.9	0
26	The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. <i>Rheumatology</i> , 2022, 61, e255-e266.	0.9	6
27	Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results. <i>Clinical Rheumatology</i> , 2022, 41, 3035-3047.	1.0	4
28	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	3.5	182
29	Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: <scp>Threeâ€Year</scp> Results From a Phase <scp>Ib</scp> Randomized Controlled Trial and Its <scp>Openâ€Label</scp> Extension Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1959-1970.	2.9	16
30	Comparing the Patientâ€Reported Physical Function Outcome Measures in a Realâ€Life International Cohort of Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 593-602.	1.5	12
31	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLAâ€B27 Status?. <i>Arthritis Care and Research</i> , 2021, 73, 856-860.	1.5	43
32	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 58-66.	1.0	5
33	Antirheumatic Disease Therapies for the Treatment of COVIDâ€19: A Systematic Review and Metaâ€Analysis. <i>Arthritis and Rheumatology</i> , 2021, 73, 36-47.	2.9	52
34	Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance. <i>Lancet Rheumatology</i> , The, 2021, 3, e28-e39.	2.2	13
35	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysisâ€Correction. <i>Journal of Investigative Dermatology</i> , 2021, 141, 177-181.	0.3	5
36	Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. <i>Rheumatology</i> , 2021, 60, 1588-1592.	0.9	4

#	ARTICLE	IF	CITATIONS
37	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 1137-1147.	0.9	13
38	Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. <i>Journal of Rheumatology</i> , 2021, 48, 1268-1271.	1.0	4
39	GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201681.	1.0	14
40	Whatâ€™influences patientsâ€™™ opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study. <i>Rheumatology</i> , 2021, 60, 5292-5299.	0.9	4
41	Treating to target in psoriatic arthritis: assessing real-world outcomes and optimising therapeutic strategy for adults with psoriatic arthritisâ€™”study protocol for the MONITOR-PsA study, a trials within cohorts study design. <i>Trials</i> , 2021, 22, 185.	0.7	5
42	Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021, , jrheum.201675.	1.0	3
43	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , 2021, 23, 94.	1.6	9
44	Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. <i>Journal of Rheumatology</i> , 2021, , jrheum.201674.	1.0	9
45	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2021, , jrheum.201679.	1.0	2
46	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. <i>Lancet Rheumatology</i> , The, 2021, 3, e270-e283.	2.2	19
47	P184â€™Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial. <i>Rheumatology</i> , 2021, 60, .	0.9	2
48	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 367-386.	1.6	2
49	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1547-1551.	1.0	3
50	JAK1 selective inhibitors for the treatment of spondyloarthropathies. <i>Rheumatology</i> , 2021, 60, ii39-ii44.	0.9	6
51	A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action. <i>Joint Bone Spine</i> , 2021, 88, 105175.	0.8	14
52	The road to personalised medicine in psoriatic arthritis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 799-802.	1.3	0
53	Measuring Physical Function in Psoriatic Arthritis: Comparing the Multidimensional Health Assessment Questionnaire to the Health Assessment Questionnaireâ€™”Disability Index. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.200927.	1.0	1
54	Current treatments and recommendations for Psoriatic Arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2021, 35, 101680.	1.4	9

#	ARTICLE	IF	CITATIONS
55	Impact of Psoriatic Disease on Women Aged 18â€“45: Results from a Multinational Survey across 11 European Countries. <i>International Journal of Women's Dermatology</i> , 2021, 7, 697-707.	1.1	1
56	Psoriatic arthritis. <i>Nature Reviews Disease Primers</i> , 2021, 7, 59.	18.1	113
57	Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Doubleâ€“blind Withdrawal Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1663-1672.	2.9	13
58	Simulation-based design of pragmatic trials in psoriatic arthritis using propensity scores. <i>Clinical Trials</i> , 2021, 18, 541-551.	0.7	0
59	To stop or not to stop: what should we be doing with biologic DMARDs when patients undergo orthopaedic surgery?. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab057.	0.3	1
60	Exploring the Quality of Communication Between Patients with Psoriatic Arthritis and Physicians: Results of a Global Online Survey. <i>Rheumatology and Therapy</i> , 2021, 8, 1741-1758.	1.1	3
61	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1117-1124.	1.6	4
62	How should we define disease and outcomes in axial psoriatic arthritis?. <i>Lancet Rheumatology</i> , The, 2021, 3, e677-e678.	2.2	2
63	Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 582-590.	0.5	105
64	Comparing the Visual Analog Scale and the Numerical Rating Scale in Patient-reported Outcomes in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 836-840.	1.0	5
65	Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab076.	0.3	4
66	Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e001845.	1.8	11
67	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579.	1.2	30
68	Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR). <i>Rheumatology</i> , 2020, 59, 1495-1504.	0.9	18
69	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 854-864.	1.0	10
70	Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry Study. <i>Journal of Rheumatology</i> , 2020, 47, 548-552.	1.0	24
71	Long-term follow-up of patients in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Rheumatology</i> , 2020, 59, 807-810.	0.9	8
72	Comparing Psoriatic Arthritis Low-field Magnetic Resonance Imaging, Ultrasound, and Clinical Outcomes: Data from the TICOPA Trial. <i>Journal of Rheumatology</i> , 2020, 47, 1338-1343.	1.0	10

#	ARTICLE	IF	CITATIONS
73	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	1.5	39
74	Prevalence of Psoriatic Arthritis Patients Achieving Minimal Disease Activity in Real-world Studies and Randomized Clinical Trials: Systematic Review with Metaanalysis. <i>Journal of Rheumatology</i> , 2020, 47, 839-846.	1.0	17
75	Treatment-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. <i>Arthritis Care and Research</i> , 2020, 72, 814-821.	1.5	6
76	Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1161-1173.	1.3	32
77	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa032.	0.3	3
78	BSR Spondyloarthritis Course, 27 February 2020. Spondyloarthritis: pathogenesis, diagnosis and management. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa043.	0.3	0
79	Treat to target in PsA should focus on clinical measures. Response to: "DAPSA versus cDAPSA: do we need to use CRP?" by Gonçalves et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e143-e143.	0.5	0
80	Measuring Outcomes in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 82-109.	1.5	11
81	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1158-1181.	1.6	6
82	Performance and Predictors of Minimal Disease Activity Response in Peripheral Spondyloarthritis Patients Treated With Adalimumab. <i>Arthritis Care and Research</i> , 2020, , .	1.5	3
83	Mixed methods study of clinicians' perspectives on barriers to implementation of treat to target in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1031-1036.	0.5	13
84	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. <i>Rheumatology and Therapy</i> , 2020, 7, 553-580.	1.1	54
85	Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 709-718.	1.6	22
86	Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. <i>British Journal of Dermatology</i> , 2020, 183, 638-649.	1.4	54
87	Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 173.	1.0	25
88	Assessment of the many faces of PsA: single and composite measures in PsA clinical trials. <i>Rheumatology</i> , 2020, 59, i29-i36.	0.9	12
89	Treatment guidelines in psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, i37-i46.	0.9	111
90	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. <i>British Journal of Dermatology</i> , 2020, 183, 628-637.	1.4	131

#	ARTICLE	IF	CITATIONS
91	Treat-to-target in PsA: methods and necessity. RMD Open, 2020, 6, e001083.	1.8	27
92	Determinants of sleep impairment in psoriatic arthritis: An observational study with 396 patients from 14 countries. Joint Bone Spine, 2020, 87, 449-454.	0.8	14
93	GRAPPA Treatment Recommendations: Updates and Methods. Journal of Rheumatology, 2020, 96, 41-45.	1.0	12
94	GRAPPA 2019 Project Report. Journal of Rheumatology, 2020, 96, 53-57.	1.0	7
95	Psoriatic arthritis: An up to date overview. Indian Journal of Rheumatology, 2020, 15, 45.	0.2	5
96	Psoriatic arthritis in developing and resource-poor countries. Lancet Rheumatology, The, 2020, 2, e200-e202.	2.2	1
97	Response to: 'To DAPSA or not to DAPSA? That is not the question' by Schoels et al. Annals of the Rheumatic Diseases, 2019, 78, e62-e62.	0.5	0
98	Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients. Rheumatology and Therapy, 2019, 6, 521-528.	1.1	18
99	Gender equity in clinical practice, research and training: Where do we stand in rheumatology?. Joint Bone Spine, 2019, 86, 669-672.	0.8	19
100	Should Methotrexate Have Any Place in the Treatment of Psoriatic Arthritis?. Rheumatic Disease Clinics of North America, 2019, 45, 325-339.	0.8	10
101	Secukinumab provides rapid and sustained resolution of enthesitis in psoriatic arthritis patients: pooled analysis of two Phase 3 studies, FUTURE 2 and FUTURE 3. Rheumatology, 2019, 58, .	0.9	0
102	Precision medicine in psoriatic arthritis: how should we select targeted therapies?. Lancet Rheumatology, The, 2019, 1, e66-e73.	2.2	4
103	The Role of Ultrasound in Psoriatic Arthritis " Do We Need a Score?. Journal of Rheumatology, 2019, 46, 337-339.	1.0	6
104	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. Journal of Rheumatology, 2019, 46, 996-1005.	1.0	36
105	ACHIEVEMENT OF CDAPSA LOW DISEASE ACTIVITY OR REMISSION IS ASSOCIATED WITH CONTROL OF ARTICULAR AND EXTRA-ARTICULAR MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN SUBJECTS TREATED WITH APREMILAST. , 2019, , .		1
106	ACHIEVEMENT OF RAPID3 NEAR REMISSION OR LOW SEVERITY IS ASSOCIATED WITH RESIDUAL LEVELS OF ARTICULAR AND EXTRA-ARTICULAR MANIFESTATIONS OF ACTIVE PSORIATIC ARTHRITIS IN SUBJECTS TREATED WITH APREMILAST. , 2019, , .		0
107	NON TOPICAL PHARMACOLOGICAL TREATMENT OF EARLY, UNTREATED (DMARD-NAIVE, SYSTEMIC) Psoriatic Arthritis. Journal of Rheumatology, 2019, 46, 1006-1012.	0.7843	0
108	Measurement properties of the minimal disease activity criteria for psoriatic arthritis. RMD Open, 2019, 5, e001002.	1.8	19

#	ARTICLE	IF	CITATIONS
109	Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies. <i>Arthritis Research and Therapy</i> , 2019, 21, 266.	1.6	17
110	Neue Ansätze beim Management der Psoriasis-Arthritis: Können wir zielgerichtet behandeln?. <i>Karger Kompass Autoimmun</i> , 2019, 1, 8-16.	0.0	0
111	What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?. <i>Journal of Rheumatology</i> , 2019, 46, 38-42.	1.0	24
112	Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study. <i>Rheumatology</i> , 2019, 58, 144-148.	0.9	24
113	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	1.0	43
114	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 31-58.	0.3	12
115	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	0.5	59
116	Assessing Disease Activity in Psoriatic Arthritis: A Literature Review. <i>Rheumatology and Therapy</i> , 2019, 6, 23-32.	1.1	43
117	Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. <i>Rheumatology</i> , 2019, 58, 1025-1033.	0.9	13
118	Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value. <i>Journal of Rheumatology</i> , 2019, 46, 160-165.	1.0	19
119	Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab. <i>Rheumatology</i> , 2019, 58, 522-526.	0.9	8
120	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	2.9	312
121	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	1.5	264
122	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 251-265.e19.	0.6	362
123	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	1.0	14
124	Best-practice Indicators in Psoriatic Disease Care. <i>Journal of Rheumatology</i> , 2019, 95, 38-45.	1.0	5
125	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019, 95, 54-57.	1.0	7
126	Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA). <i>RMD Open</i> , 2018, 4, e000606.	1.8	17



#	ARTICLE	IF	CITATIONS
127	Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1530-1534.	1.3	11
128	Minimal Disease Activity Among Active Psoriatic Arthritis Patients Treated With Secukinumab: 2-Year Results From a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study. <i>Arthritis Care and Research</i> , 2018, 70, 1529-1535.	1.5	39
129	A new era for collaboration?. <i>Rheumatology</i> , 2018, 57, 775-776.	0.9	0
130	Cost-Effectiveness of Tight Control of Inflammation in Early Psoriatic Arthritis: Economic Analysis of a Multicenter Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2018, 70, 462-468.	1.5	12
131	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
132	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e23-e23.	0.5	16
133	How routine use of a treat to target approach in PsA might impact on clinical decision making. <i>Rheumatology</i> , 2018, 57, 209-210.	0.9	1
134	Remission in psoriatic arthritis—where are we now?. <i>Rheumatology</i> , 2018, 57, 1321-1331.	0.9	16
135	Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 251-257.	0.5	46
136	Considerations for the definition of remission criteria in psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 786-796.	1.6	38
137	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	2.9	72
138	Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis: Results From a Tight-Control Clinical Trial and an Observational Cohort. <i>Arthritis Care and Research</i> , 2018, 70, 1198-1205.	1.5	29
139	Current concepts and unmet needs in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2018, 37, 297-305.	1.0	26
140	Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2018, 5, 567-582.	1.1	43
141	Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study. <i>Arthritis Research and Therapy</i> , 2018, 20, 272.	1.6	30
142	Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. <i>Arthritis Research and Therapy</i> , 2018, 20, 242.	1.6	24
143	Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity. <i>Drugs</i> , 2018, 78, 1705-1715.	4.9	19
144	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2018, 392, 2367-2377.	6.3	159

#	ARTICLE	IF	CITATIONS
145	Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?. Current Rheumatology Reports, 2018, 20, 71.	2.1	23
146	Classification and Outcome Measures for Psoriatic Arthritis. Frontiers in Medicine, 2018, 5, 246.	1.2	20
147	Clinical management of psoriatic arthritis. Lancet, The, 2018, 391, 2285-2294.	6.3	96
148	Personalized medicine "a new reality in psoriatic arthritis?. Nature Reviews Rheumatology, 2018, 14, 449-451.	3.5	4
149	Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity. BMC Rheumatology, 2018, 2, 24.	0.6	24
150	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. Journal of Rheumatology, 2018, 94, 17-25.	1.0	10
151	THU0314...Ixekizumab makes very low disease activity and remission with psoriatic arthritis disease activity score possible in active psoriatic arthritis patients for up to 1 year: spirit-p1 and spirit-p2 trials. , 2018, , .		0
152	The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database. Journal of Rheumatology, 2018, 94, 26-29.	1.0	5
153	THU0284...Haq in psoriatic arthritis is driven by gender, inflammation and ageing: observational data from cohort studies in uk, denmark, iceland and sweden. , 2018, , .		0
154	GRAPPA 2017 Project Report. Journal of Rheumatology, 2018, 94, 48-51.	1.0	3
155	Report of the Skin Research Working Groups from the GRAPPA 2017 Annual Meeting. Journal of Rheumatology, 2018, 94, 40-43.	1.0	2
156	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. Journal of Rheumatology, 2017, 44, 1522-1528.	1.0	93
157	New GRAPPA and EULAR recommendations for the management of psoriatic arthritis. Rheumatology, 2017, 56, kew390.	0.9	36
158	Psoriatic arthritis: state of the art review. Clinical Medicine, 2017, 17, 65-70.	0.8	198
159	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Annals of the Rheumatic Diseases, 2017, 76, 673-680.	0.5	194
160	GRAPPA 2016 Project Report. Journal of Rheumatology, 2017, 44, 706-710.	1.0	2
161	Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Annals of the Rheumatic Diseases, 2017, 76, 1591-1597.	0.5	52
162	International Treatment Recommendations Update: A Report from the GRAPPA 2016 Annual Meeting. Journal of Rheumatology, 2017, 44, 684-685.	1.0	4

#	ARTICLE	IF	CITATIONS
163	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	1.0	42
164	Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 703-705.	1.0	7
165	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. <i>British Journal of Dermatology</i> , 2017, 177, 628-636.	1.4	226
166	Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients. <i>Rheumatology and Therapy</i> , 2017, 4, 219-231.	1.1	44
167	The dynamics of response as measured by multiple composite outcome tools in the Tight Control of inflammation in early Psoriatic Arthritis (TICOPA) trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1688-1692.	0.5	17
168	The Changing Face of Clinical Trials in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2017, 19, 21.	2.1	29
169	Patient education and screening for psoriatic arthritis is key in the care of patients with psoriasis, whichever method is chosen. <i>British Journal of Dermatology</i> , 2017, 176, 574-575.	1.4	1
170	An educational leaflet improves response to invitation for screening for arthritis in patients with psoriasis in primary care, but only in practices in the most deprived areas. <i>Clinical Rheumatology</i> , 2017, 36, 719-723.	1.0	1
171	Psoriatic arthritis: lessons from imaging studies and implications for therapy. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 133-142.	1.3	22
172	Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. <i>RMD Open</i> , 2017, 3, e000415.	1.8	24
173	SAT0469â€¦Integrated efficacy analysis of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis. , 2017, , .		1
174	Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1. <i>RMD Open</i> , 2017, 3, e000567.	1.8	24
175	FRI0509â€¦Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from opal balance, an open-label, long-term extension study. , 2017, , .		7
176	O69.â€¦CONSTRUCT VALIDITY, RESPONSIVENESS AND MINIMALLY IMPORTANT DIFFERENCE OF THE ROUTINE ASSESSMENT OF PATIENT INDEX DATA 3 IN PSORIATIC ARTHRITIS. <i>Rheumatology</i> , 2017, 56, .	0.9	0
177	SAT0464â€¦The ideal target for psoriatic arthritis? comparison of remission and inactive disease states in a real life cohort. , 2017, , .		1
178	FRI0463â€¦Secukinumab Improves Minimal Disease Activity Response Rates in Patients with Active Psoriatic Arthritis: Data from The Randomized Phase 3 Study, Future 2. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 605.1-605.	0.5	4
179	New GRAPPA recommendations for the management of psoriasis and psoriatic arthritis: process, challenges and implementation. <i>British Journal of Dermatology</i> , 2016, 174, 1174-1178.	1.4	39
180	Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. <i>Nature Reviews Rheumatology</i> , 2016, 12, 743-750.	3.5	71

#	ARTICLE	IF	CITATIONS
181	Letâ€™s Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. Journal of Rheumatology, 2016, 43, 970-973.	1.0	6
182	A discrete choice experiment to explore patientsâ€™ willingness to risk disease relapse from treatment withdrawal in psoriatic arthritis. Clinical Rheumatology, 2016, 35, 2967-2974.	1.0	9
183	GRAPPA 2015 Research and Education Project Reports. Journal of Rheumatology, 2016, 43, 979-985.	1.0	3
184	Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?. Seminars in Arthritis and Rheumatism, 2016, 46, 291-304.	1.6	119
185	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1060-1071.	2.9	726
186	Comparison of screening questionnaires to identify psoriatic arthritis in a primary-care population: a cross-sectional study. British Journal of Dermatology, 2016, 175, 542-548.	1.4	25
187	Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study. Journal of Rheumatology, 2016, 43, 356-361.	1.0	89
188	Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments. Journal of Rheumatology, 2016, 43, 371-375.	1.0	87
189	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placeboâ€™Controlled Study. Arthritis Care and Research, 2016, 68, 267-274.	1.5	69
190	Psoriasis flare with corticosteroid use in psoriatic arthritis. British Journal of Dermatology, 2016, 174, 219-221.	1.4	15
191	Treating to target in psoriatic arthritis: how to implement in clinical practice. Annals of the Rheumatic Diseases, 2016, 75, 640-643.	0.5	38
192	Paradigms of Treatment in PsA. , 2016, , 243-252.		1
193	Implementing the findings of the TICOPA trial in clinical practice: challenges in implementation and how information technology can bridge the gap. Clinical and Experimental Rheumatology, 2016, 34, S73-S74.	0.4	17
194	SAT0556â€™.Methotrexate Efficacy in Early Psoriatic Arthritis â€™ Open Label Data from the Ticopa Study. Annals of the Rheumatic Diseases, 2015, 74, 861.2-861.	0.5	1
195	THU0426â€™.Ultrasound Identifies Additional Erosive Disease in Patients with Early Psoriatic Arthritis â€™ Results from the Ticopa Study:. Annals of the Rheumatic Diseases, 2015, 74, 353.1-353.	0.5	1
196	A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis		

#	ARTICLE	IF	CITATIONS
199	Treating to target in psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 107-110.	2.0	19
200	Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 2489-2498.	6.3	389
201	Outcome Measures in Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 699-710.	0.8	15
202	The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains?. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e66-e66.	0.5	10
203	Therapy strategies in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S70-2.	0.4	1
204	The involvement of the spine in psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S31-5.	0.4	33
205	Development of a Disease Activity and Responder Index for Psoriatic Arthritis â€” Report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , 2014, 41, 782-791.	1.0	34
206	Is There Subclinical Synovitis in Early Psoriatic Arthritis? A Clinical Comparison With Grayâ€™Scale and Power Doppler Ultrasound. <i>Arthritis Care and Research</i> , 2014, 66, 432-439.	1.5	79
207	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. <i>Arthritis Care and Research</i> , 2014, 66, 1410-1416.	1.5	21
208	Systematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the GRAPPA. <i>Journal of Rheumatology</i> , 2014, 41, 2273-2276.	1.0	37
209	Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2014, 41, 2277-2285.	1.0	51
210	Patient Involvement in Outcome Measures for Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2014, 16, 418.	2.1	34
211	GRAPPA Treatment Recommendations: An Update from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1237-1239.	1.0	22
212	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	1.5	73
213	SAT0406â€¦Low Level of Erosive Change is Found in Early Psoriatic Arthritis:. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 741.2-742.	0.5	0
214	The TICOPA protocol (Tight CONTROL of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis. <i>BMC Musculoskeletal Disorders</i> , 2013, 14, 101.	0.8	89
215	Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST) Tj ETQq1 1 0,784314 rãBT /Ovle	1.4	130
216	Brief Report: Reduced Joint Counts Misclassify Patients With Oligoarticular Psoriatic Arthritis and Miss Significant Numbers of Patients With Active Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 1504-1509.	6.7	60

#	ARTICLE	IF	CITATIONS
217	The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. <i>Rheumatology</i> , 2013, 52, 1754-1757.	0.9	79
218	SAT0305â€¦MDA criteria for PSA show good correlation with physician and patient opinions and with proposed composite measures. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 575.2-575.	0.5	2
219	Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 358-362.	0.5	57
220	MRI and ultrasonography for diagnosis and monitoring of psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 805-822.	1.4	76
221	Summary of the International Federation of Psoriasis Associations (IFPA) Meeting: A Report from the GRAPPA 2009 Annual Meeting. <i>Journal of Rheumatology</i> , 2011, 38, 530-539.	1.0	3
222	Development of a preliminary composite disease activity index in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 272-277.	0.5	184
223	The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Score (PsAMRIS) Is Reliable and Sensitive to Change: Results from an OMERACT Workshop. <i>Journal of Rheumatology</i> , 2011, 38, 2034-2038.	1.0	66
224	GRAPPA Trainees Symposium 2009: A Report from the GRAPPA 2009 Annual Meeting: Table 1.. <i>Journal of Rheumatology</i> , 2011, 38, 526-529.	1.0	11
225	Disease measurement â€œ enthesitis, skin, nails, spine and dactylitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 659-670.	1.4	31
226	Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. <i>Arthritis Care and Research</i> , 2010, 62, 965-969.	1.5	201
227	Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. <i>Arthritis Care and Research</i> , 2010, 62, 970-976.	1.5	110
228	Imaging in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 448-452.	1.0	18
229	Testing an OMERACT MRI Scoring System for Peripheral Psoriatic Arthritis in Cross-sectional and Longitudinal Settings. <i>Journal of Rheumatology</i> , 2009, 36, 1811-1815.	1.0	29
230	The OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System (PsAMRIS): Definitions of Key Pathologies, Suggested MRI Sequences, and Preliminary Scoring System for PsA Hands. <i>Journal of Rheumatology</i> , 2009, 36, 1816-1824.	1.0	168
231	Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review. <i>Journal of Rheumatology</i> , 2008, 35, 1438-42.	1.0	33
232	The need for clarity on the use of glucocorticoids for people with psoriatic arthritis: A call for consensus. <i>Rheumatology</i> , 0, , .	0.9	0
233	Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study. <i>Patient</i> , 0, , .	1.1	3